Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates <i>In Vivo</i> Antitumor Activity-Reference-Cited by-同舟云学术

Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates In Vivo Antitumor Activity

Published:2022-12-19 Issue:1 Volume:66 Page:345-370
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Li Jim¹^ORCID,Chen Lijing¹,Billedeau Roland J.¹,Stanton Timothy F.¹,Chiang John T. P.¹,Lee Clarissa C.¹,Li Weiqun¹,Steggerda Susanne¹,Emberley Ethan¹,Gross Matthew¹,Bhupathi Deepthi¹,Che Xiaoying²,Chen Jason¹,Dang Rosalyn¹,Huang Tony¹,Ma Yong¹^ORCID,MacKinnon Andrew¹,Makkouk Amani¹,Marguier Gisele¹,Neou Silinda¹,Sotirovska Natalija¹,Spurlock Sandra¹,Zhang Jing¹,Zhang Winter¹,van Zandt Michael³^ORCID,Yuan Lin³,Savoy Jennifer³,Parlati Francesco¹,Sjogren Eric B.¹

Affiliation:

1. Calithera Biosciences, 343 Oyster Point Boulevard, South San Francisco, California 94080, United States

2. Wuxi AppTec, Shanghai 200131, China

3. NEDP, Branford, Connecticut 06405, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01287

Reference53 articles.

1. Hallmarks of Cancer: The Next Generation